2025.12.05 (금)

  • 맑음속초2.4℃
  • 맑음-4.2℃
  • 맑음철원-6.5℃
  • 맑음동두천-3.8℃
  • 맑음파주-5.0℃
  • 맑음대관령-6.7℃
  • 맑음춘천-1.2℃
  • 구름조금백령도4.2℃
  • 맑음북강릉0.4℃
  • 맑음강릉2.4℃
  • 맑음동해0.7℃
  • 맑음서울-0.8℃
  • 맑음인천-0.4℃
  • 맑음원주-3.5℃
  • 맑음울릉도2.6℃
  • 맑음수원-1.5℃
  • 맑음영월-2.9℃
  • 맑음충주-4.8℃
  • 맑음서산-1.2℃
  • 맑음울진1.8℃
  • 맑음청주0.6℃
  • 맑음대전-0.4℃
  • 맑음추풍령-0.8℃
  • 맑음안동-0.9℃
  • 맑음상주0.2℃
  • 맑음포항2.7℃
  • 맑음군산0.3℃
  • 맑음대구2.6℃
  • 맑음전주0.5℃
  • 맑음울산2.2℃
  • 맑음창원3.2℃
  • 맑음광주2.0℃
  • 맑음부산2.9℃
  • 맑음통영2.7℃
  • 맑음목포2.4℃
  • 맑음여수3.6℃
  • 맑음흑산도3.5℃
  • 맑음완도2.1℃
  • 맑음고창-0.5℃
  • 맑음순천0.6℃
  • 맑음홍성(예)-0.7℃
  • 맑음-2.6℃
  • 맑음제주6.3℃
  • 맑음고산6.0℃
  • 맑음성산4.1℃
  • 구름많음서귀포8.3℃
  • 맑음진주-0.4℃
  • 맑음강화-3.9℃
  • 맑음양평-2.6℃
  • 맑음이천-3.3℃
  • 맑음인제-1.9℃
  • 맑음홍천-3.6℃
  • 맑음태백-2.6℃
  • 맑음정선군-3.1℃
  • 맑음제천-6.0℃
  • 맑음보은-2.6℃
  • 구름조금천안-2.9℃
  • 맑음보령-1.4℃
  • 맑음부여-0.9℃
  • 맑음금산-2.3℃
  • 맑음-0.3℃
  • 맑음부안0.4℃
  • 맑음임실-1.4℃
  • 맑음정읍-0.2℃
  • 맑음남원-0.5℃
  • 맑음장수-3.4℃
  • 맑음고창군-0.9℃
  • 맑음영광군-0.3℃
  • 맑음김해시2.0℃
  • 맑음순창군-1.0℃
  • 맑음북창원3.1℃
  • 맑음양산시2.0℃
  • 맑음보성군2.5℃
  • 맑음강진군1.4℃
  • 맑음장흥1.9℃
  • 맑음해남2.2℃
  • 맑음고흥1.0℃
  • 맑음의령군-2.5℃
  • 맑음함양군-0.8℃
  • 맑음광양시2.2℃
  • 맑음진도군3.2℃
  • 맑음봉화-1.7℃
  • 맑음영주-0.8℃
  • 맑음문경-1.6℃
  • 맑음청송군-1.0℃
  • 맑음영덕1.1℃
  • 맑음의성-2.8℃
  • 맑음구미-0.7℃
  • 맑음영천1.1℃
  • 맑음경주시-0.7℃
  • 맑음거창-2.4℃
  • 맑음합천0.1℃
  • 맑음밀양1.0℃
  • 맑음산청-0.4℃
  • 맑음거제0.8℃
  • 맑음남해2.2℃
  • 맑음0.1℃
기상청 제공
Shoppy 로고
Boehringer Ingelheim announces appointments to Board of Managing Directors
  • 해당된 기사를 공유합니다

산업 경제 뉴스

Boehringer Ingelheim announces appointments to Board of Managing Directors

Paola Casarosa appointed member of the Board of Managing Directors per July 1, 2023, with responsibility for the Innovation Unit per January 1, 2024.
Shashank Deshpande appointed member of the Board of Managing Directors per September 1, 2023, with responsibility for the Animal Health Business Unit per January 1, 2024.
Michel Pairet and Jean Scheftsik de Szolnok to retire at the end of 2023.

Boehringer Ingelheim today announces that the Shareholders have appointed Paola Casarosa and Shashank Deshpande to the Board of Managing Directors. They will succeed Michel Pairet, responsible for the Innovation Unit, and Jean Scheftsik de Szolnok, responsible for the Animal Health Business Unit, who informed the Shareholders of their wish to retire at the end of next year.

Paola Casarosa will succeed Michel Pairet to head the Innovation Unit. Paola joined Boehringer Ingelheim in 2007 and is currently Global Head of Therapeutic Areas in the Human Pharma Business Unit. Prior to this role, she held various leadership roles in Business Development and in Research. Paola is an Italian national, holds a PhD in Molecular Pharmacology and a Masters’ degree in Medicinal Chemistry.

Shashank Deshpande will succeed Jean Scheftsik de Szolnok to head the Animal Health Business Unit. Shashank joined Boehringer Ingelheim in 2012 and is currently Country Managing Director Japan. Prior to this role he held several leadership and marketing positions in Japan and Ingelheim. A German and US national, Shashank holds a Masters’ degree in Business Administration.

Christian Boehringer, Chairman of the Shareholders’ Committee said: “Our long-term planning allows for a seamless transition. On behalf of the Shareholders, I want to thank Michel and Jean for their many years of dedication to our company and I congratulate Paola and Shashank on their appointments.”

Hubertus von Baumbach, Chairman of the Board of Managing Directors, added: “I am grateful for the long time that I have had the privilege to work with Michel and Jean and I look forward to continuing to work with them until the end of 2023. The Board is excited to welcome Paola and Shashank to the team later next year.”

The appointment to the Board of Managing Directors will be effective July 1, 2023 for Paola Casarosa and September 1, 2023 for Shashank Deshpande.

Click here for the full release: https://www.boehringer-ingelheim.com/about-us/boehringer-ingelheim-appointment-board-managing-directors

View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005424/en/

언론연락처: Boehringer Ingelheim Médard Schoenmaeckers Boehringer Ingelheim Corporate Affairs

이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.




포토

 
모바일 버전으로 보기